Acute human bocavirus 1 infection in child with life-threatening bilateral bronchiolitis and right-sided pneumonia: a case report by Ziemele, Inga et al.
CASE REPORT Open Access
Acute human bocavirus 1 infection in child
with life-threatening bilateral bronchiolitis
and right-sided pneumonia: a case report
Inga Ziemele1,2*, Man Xu3, Anda Vilmane4, Santa Rasa-Dzelzkaleja4, Lea Hedman3,5, Klaus Hedman3,5,
Maria Söderlund-Venermo3, Zaiga Nora-Krukle4, Modra Murovska4 and Dace Gardovska1,2
Abstract
Background: Human bocavirus 1 is a commonly detected human parvovirus. Many studies have shown human
bocavirus 1 as a pathogen in association with acute respiratory tract infections in children. However, because
human bocavirus 1 persists in the upper airways for extensive time periods after acute infection, the definition and
diagnostics of acute human bocavirus 1 infection is challenging. Until now, detection of human bocavirus 1
exclusively, high viral load in respiratory samples, and viremia have been associated with a clinical picture of acute
respiratory illness. There are no studies showing detection of human bocavirus 1 messenger ribonucleic acid in the
peripheral blood mononuclear cells as a diagnostic marker for acute lower respiratory tract infection.
Case presentation: We report the case of a 17-month-old Latvian boy who presented in intensive care unit with
acute bilateral bronchiolitis, with a history of rhinorrhea and cough for 6 days and fever for the last 2 days prior to
admission, followed by severe respiratory distress and tracheal intubation. Human bocavirus 1 was the only
respiratory virus detected by a qualitative multiplex polymerase chain reaction panel. For the diagnosis of acute
human bocavirus 1 infection, both molecular and serological approaches were used. Human bocavirus 1
deoxyribonucleic acid (DNA) was detected simultaneously in nasopharyngeal aspirate, stool, and blood, as well as in
the corresponding cell-free blood plasma by qualitative and quantitative polymerase chain reaction, revealing high
DNA-copy numbers in nasopharyngeal aspirate and stool. Despite a low-load viremia, human bocavirus 1
messenger ribonucleic acid was found in the peripheral blood mononuclear cells. For detection of human
bocavirus 1-specific antibodies, non-competitive immunoglobulin M and competitive immunoglobulin G enzyme
immunoassays were used. The plasma was positive for both human bocavirus 1-specific immunoglobulin M and
immunoglobulin G antibodies.
Conclusions: The presence of human bocavirus 1 genomic DNA in blood plasma and human bocavirus 1
messenger ribonucleic acid in peripheral blood mononuclear cells together with human bocavirus 1-specific
immunoglobulin M are markers of acute human bocavirus 1 infection that may cause life-threatening acute
bronchiolitis.
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Background
Acute lower respiratory tract infections (LRTIs) are re-
sponsible for significant morbidity and mortality in infants
and young children worldwide. Childhood pneumonia ac-
counts for 16% of all deaths of children under 5 years of
age and 7–13% of all community cases are life-threatening
and require hospitalization. The most common causes of
acute LRTIs with divergent presentation are viruses. Re-
spiratory syncytial virus (RSV) is the most common viral
cause of pneumonia in young children [1, 2].
Human bocavirus 1 (HBoV1), the second human
pathogenic virus in the family Parvoviridae, was discov-
ered in 2005 in nasopharyngeal aspirates (NPAs) of chil-
dren with acute respiratory tract infection (ARTI) [3].
Since then, HBoV1-associated ARTIs have been reported
worldwide [4].
On the one hand, there are studies showing evidence
of HBoV1 as a pathogen in association with LRTIs,
mainly in children up to 3 years of age [5–10]. On the
other hand, HBoV1 has also been found in asymptom-
atic children [11–14]. These states of affairs at first may
seem contradictory; however, HBoV1 has been shown to
remain in the nasopharynx for several weeks and even
months, thereby causing clinically false polymerase chain
reaction (PCR) diagnoses. Moreover, life-threatening and
even fatal HBoV1 infections have been reported [15–19].
The definition and diagnosis of acute HBoV1 respiratory
tract infection is challenging. Detection of HBoV1
deoxyribonucleic acid (DNA) in blood, messenger ribo-
nucleic acid (mRNA), and viral load assessment in re-
spiratory samples and serology have been recommended
as the markers to diagnose active HBoV1 infection [6, 7,
20, 21]. According to the best of our knowledge, there
are no studies up to now showing detection of HBoV1
mRNA in the peripheral blood mononuclear cells
(PBMCs) as a diagnostic marker for acute HBoV1
infection.
In this study, we report an acute HBoV1 infection in
an otherwise healthy child with life-threatening acute bi-
lateral bronchiolitis and right-side pneumonia with de-
tected HBoV1-specific immunoglobulin (Ig) M and
DNA in cell-free blood plasma as well as HBoV1 mRNA
in PBMC.
Case report
A 17-month-old Latvian boy was admitted to the Chil-
dren’s Clinical University Hospital of Riga, Latvia, on the
seventh day of illness in January 2015. He presented with
a history of rhinorrhea and cough for 6 days and fever
(axillar temperature 39.0 °C) for the last 2 days prior to
admission. Due to severe respiratory distress, he was im-
mediately transferred from the regional hospital to our
intensive care unit.
On admission, his respiratory rate was 44 breaths/mi-
nute (reference 20–30), heart rate 146 beats/minute (ref-
erence 80–130), oxygen saturation 99% (with an oxygen
flow of 5 liters/minute via face mask), and axillary
temperature 38.7 °C. Auscultation of his lungs revealed
bilateral wheezing and crepitation with severe intercostal
and subcostal recessions. The other organ systems were
without pathology. Due to the severe respiratory distress,
tracheal intubation was performed.
The child had been born full term as the seventh in
the family. He had no known underlying illness, history
of previous hospitalizations, or severe acute illnesses. He
had been fully immunized according to the national
immunization scheme.
On admission, his white blood cell (WBC) count was
30.6 × 103/μL with 66.9% of granulocytes (in absolute
numbers 20.6 × 103/μL), hemoglobin 12.4 g/dL, and
platelet count 321 × 103/μL. His C-reactive protein
(CRP) was 5.09 mg/L. A chest radiograph showed infil-
tration of the upper lobe of his right lung (Fig. 1).
At the time of admission, a nasopharyngeal swab
(NPS) tested negative by direct immunofluorescence
(IMAGEN™ OXOID, UK) for antigens of RSV, influenza
virus A and B, parainfluenza virus types 1–3, and adeno-
virus. Bacterial blood cultures were negative. NPA,
blood, and stool samples were collected for HBoV1 mo-
lecular diagnostics and serology.
NPA tested by qualitative multiplex PCR (Seegene Re-
spiratory Panel, South Korea) was negative for: influenza
virus A and B; RSV A and B; flu A types H1, H1pdm09,
and H3; adenovirus; enterovirus; parainfluenza virus
Fig. 1 Chest radiograph (anteroposterior view) of the patient on the
first day of hospitalization, showing upper right-side pneumonia
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types 1–4; metapneumovirus; rhinovirus; and corona-
virus types NL63, 229E, and OC43. However, the NPA
tested by qualitative multiplex PCR was positive for
HBoV1. NPA, whole blood with corresponding cell-free
blood plasma, and stool samples underwent qualitative
PCR for HBoV1 NS1 DNA, as described [20]. An
HBoV1-containing plasmid was used as a positive control
in PCR. All these samples were HBoV1 DNA positive.
Upon re-examination by quantitative PCR (qPCR) (Hu-
man bocavirus genomes, Standard kit, Genesig, Primerde-
sign Ltd., UK), the copy numbers in NPA and stool were
high, 5.7 × 105 per μg DNA in NPA and 1.4 × 108 per μg
DNA in stool. The viral load in blood was 21 copies/μg
DNA, but in cell-free blood plasma the viral load was
under detection level.
To prove that the HBoV1 infection was actively on-
going, HBoV1 transcription in PBMCs was applied.
Total ribonucleic acid (RNA) was extracted from
PBMCs using TRI Reagent® solution according to the
manufacturer’s instructions (Thermo Fisher Scientific,
USA). The extracted RNA was quantified spectrophoto-
metrically and analyzed by electrophoresis in a 1% agar-
ose gel. RNA was treated with DNase (TURBO DNA-
free™ Kit, Thermo Fisher Scientific, USA) before the syn-
thesis of complementary DNA (cDNA) by the reverse
transcriptase (RT) using RevertAid™ First Strand cDNA
Synthesis Kit (Thermo Fisher Scientific, USA). The β-
actin gene sequence was detected by PCR to assess the
quality of synthesized cDNA (Fig. 2).
HBoV1-specific cDNA was detected by PCR targeting
the HBoV1 NS1 gene as described by Sloots et al., in
2006, followed by electrophoretic visualization of the
amplification products in a 1.7% agarose gel (Fig. 3) [22].
The same DNase-treated RNA sample but without the
RT step, served as a negative control in both the β-glo-
bin and HBoV1 PCRs to make sure that there was no
contamination with DNA.
Biotinylated virus-like particles (VLPs) of the re-
combinant major capsid protein VP3 were used as antigen
in enzyme immunoassays (EIAs) for detection of HBoV1-
specific immunoglobulin M (IgM) and immunoglobulin G
(IgG) in our patient’s plasma sample [23, 24]. For removal
of possible cross-reacting heterologous human bocavirus 2
(HBoV2) and human bocavirus 3 (HBoV3) IgG, non-bio-
tinylated VLPs in competition assays were used as described
[24]. Our patient’s plasma sample was positive for both
HBoV1-specific IgM and IgG antibodies.
Because of the right lung upper lobe infiltration and in-
creased WBC initially, the child was treated with intraven-
ously administered ceftriaxone 350mg twice a day for 7
days and per-oral oseltamivir 30mg twice a day (due to in-
fluenza season). Oseltamivir was discontinued after 3 days
due to the negative influenza virus A and B antigen find-
ings. Extubated on day 3, our patient was brought to the
Department of Paediatrics, where intravenously adminis-
tered ceftriaxone was continued, inhalations via nebulizer
with salbutamol and budesonide were begun and pulmon-
ary rehabilitation started. During the next 10 days, the
child’s general condition improved, his body temperature
was normal, lung sounds were without the pathology, and
no additional oxygen was needed. During the
hospitalization, poor weight gain was observed for our pa-
tient; therefore, additional diagnostic tests were done and
his hospitalization length increased. On day 17 of
hospitalization, he developed a new episode of fever for 2
days. The second NPS tested negative for RSV, and influ-
enza virus A and B; however, self-limiting viral upper re-
spiratory tract infection was suspected and he was treated
with intravenously administered rehydration and ibupro-
fen 70mg for these 2 days. Due to the very low socioeco-
nomic status of the family, he was kept in the hospital
mainly for observation, although his general condition was
good. On day 30 he developed a new episode of fever,
cough, and wheezing lasting 6 days. In this episode, LRTI
was diagnosed based on the clinical symptoms and he was
treated with nebulized salbutamol and budesonide.
After 46 days of hospitalization he recovered completely
from HBoV1-associated acute bilateral bronchiolitis with
right-side pneumonia and a subsequent hospital-acquired
upper and LRTI and was discharged.
Discussion
HBoV1 is frequently found in respiratory tract samples
collected from hospitalized children with a peak age up
to 24 months [24–26]. By PCR it appears as the third
Fig. 2 Electrophoretic visualization of amplification products in a 1%
agarose gel after polymerase chain reaction targeting β-actin
gene sequence
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most common pathogen next to RSV and rhinovirus in
young children presenting with acute bronchiolitis and
wheezing [4, 27, 28]. Furthermore, serological studies
have revealed that HBoV1 acute infections occur most
often in early childhood, with HBoV1 IgG seroconvert-
ing at a median age of 1.9 years and reaching a sero-
prevalence of 80% by 6 years of age [24]. Several clinical
cases have shown severe or even life-threatening respira-
tory tract diseases due to HBoV1 infection in children
[10, 15–19, 29]. However, it should be kept in mind that,
due to HBoV1 long-term persistence in the upper air-
ways, the virus is frequently co-detected with other re-
spiratory pathogens. The diagnosis should therefore not
be based only on qualitative PCR for HBoV1 DNA in re-
spiratory samples [6, 20, 30]. Detection of HBoV1 DNA
in blood, mRNA, and viral load assessment in airway
samples and serology have been recommended as better
tools for diagnostics to separate active HBoV1 infection
from asymptomatic virus shedding [6, 7, 20, 21].
In this report, we present a case of a 17-month-old
boy with typical symptoms of acute bilateral bron-
chiolitis: initially rhinorrhea and cough followed by
difficulty in breathing and typical findings in ausculta-
tion, including wheezing and crepitation. Fever oc-
curred for 2 days before hospitalization and his WBC
was high with absolute granulocytosis. Because the
latter findings pointed to complications, chest radiog-
raphy was performed and right-sided pneumonia con-
firmed. The onset of the clinical course and normal
range CRP value, were compatible with a viral LRTI.
NPA tested by multiplex PCR was positive only for
HBoV1 DNA, while 18 other respiratory viruses,
including those which often cause severe bronchiolitis
in this age group (RSV, rhinovirus, and human
metapneumovirus), were negative. It was not surprising
that HBoV1 DNA was simultaneously found by PCR in
all samples including stool. Viral passage through the
gastrointestinal tract due to swallowing of respiratory
secretions in patients with ARTIs has been suggested
[9]. By qPCR, a high viral load was detected in NPA
and stool. Detection of HBoV1 exclusively, high HBoV1
DNA load in respiratory samples, and viremia are asso-
ciated with a clinical picture of acute LRTI [6, 7]. How-
ever, in some other cases the viral DNA has remained
detectable in blood for a prolonged time [15, 16]. In
our patient, HBoV1 PCR was also positive in cell-free
blood plasma, indicating that the virus was freed from
the cells and that he had HBoV1 viremia. Diagnosis of
acute HBoV1 infection is shown also by the presence of
circulating HBoV1-specific IgM. Moreover, to verify
that the current illness was in fact caused by acute
HBoV1 infection, we looked for and found HBoV1
mRNA in PBMCs, verifying RNA transcription. To the
best of our knowledge this is the first time HBoV1
mRNA has been detected in PBMCs, suggesting active
replication in PBMCs. Existing data support that the
detection of HBoV1 mRNA, at least in NPA, is more
accurate than that of HBoV1 DNA, in the diagnosis of
active infection [21, 31].
Conclusions
HBoV1 infection may cause life-threatening acute bron-
chiolitis, as this pediatric case demonstrates. The diagnosis
of acute HBoV1 infection was proved by the presence of
HBoV1-specific IgM and DNA in cell-free blood plasma as
well as HBoV1 mRNA in PBMCs, whereas no other viruses
or bacteria were found by PCR and culture, respectively.
Fig. 3 Electrophoretic visualization of amplification products in a 1.7% agarose gel after polymerase chain reaction targeting human bocavirus 1
NS1 gene. Legend 1: 1. pUC19 DNA/MspI (HpaII) marker; 2. negative control (molecular biology grade H2O); 3. complementary DNA sample
synthesized from DNase treated ribonucleic acid; 4. DNase treated ribonucleic acid sample without reverse transcriptase step. Legend 2: 1. pUC19
DNA/MspI (HpaII) marker; 2. DNase treated ribonucleic acid sample without reverse transcriptase step; 3. complementary DNA sample synthesized
from DNase treated ribonucleic acid; 4. negative control (molecular biology grade H2O); 5., 6. positive control (human bocavirus 1 plasmid); 7.
GeneRuler 100 bp DNA Ladder
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